Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 2:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Valsartan 80 mg Clear all
Completed Phase 3 Interventional Results available

Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure

NCT00433836
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2011 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 11, 2011 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

NCT02884206
View directory record Official record
Conditions
Chronic Heart Failure (CHF)
Interventions
LCZ696, Valsartan, Placebo of LCZ696, Placebo of Valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
592 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
52
States / cities
Andalusia, Alabama • Glendale, Arizona • Mesa, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Aliskiren and Valsartan Versus Placebo in Patients Stabilized Following an Acute Coronary Syndrome

NCT00409578
View directory record Official record
Conditions
Post Acute Coronary Syndrome, Myocardial Ischemia
Interventions
Placebo, Aliskiren 300 mg, Valsartan 320 mg, Aliskiren/valsartan 300/320 mg
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Investigative Site, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 27, 2026, 2:13 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

NCT04971720
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Interventions
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

Telmisartan vs. Valsartan in Patients With Mild to Moderate Hypertension Following a Missed Dose

NCT00034840
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan, valsartan
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
16
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)

NCT03988634
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction (HFpEF)
Interventions
sacubitril/valsartan, valsartan, sacubitril/valsartan matching placebo, valsartan matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
467 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
87
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 77 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

NCT01508026
View directory record Official record
Conditions
Stage 1 Hypertension, Stage 2 Hypertension
Interventions
Nebivolol and Valsartan 1, Nebivolol and Valsartan 2, Nebivolol and Valsartan 3, Nebivolol 1, Nebivolol 2, Valsartan 1, Valsartan 2, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
4,161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
413
States / cities
Birmingham, Alabama • Foley, Alabama • Gulf Shores, Alabama + 290 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension

NCT00591578
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan Medoxomil, Valsartan
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
984 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
77
States / cities
Huntsville, Alabama • Glendale, Arizona • Phoenix, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2012 · Synced Sep 27, 2026, 2:13 AM EDT
Terminated Not applicable Interventional Results available

Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

NCT02606279
View directory record Official record
Conditions
HIV, Aging, Sarcopenia, Angiotensin Receptor Antagonists
Interventions
valsartan, Placebo
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valsartan/Hydrochlorothiazide Combination Therapy in Patients With Hypertension

NCT00280540
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan/Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
648 participants
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2010 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Results available

EntrestoTM (LCZ696) In Advanced Heart Failure (LIFE Study)

NCT02816736
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ696, valsartan, LCZ696 placebo, valsartan placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 85 Years
Enrollment
365 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
38
States / cities
Beverly Hills, California • Sacramento, California • San Diego, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2021 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients

NCT03066804
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction
Interventions
sacubitril/valsartan, Enalapril, Valsartan, Placebo to match sacubitril/valsartan, Placebo to match enalapril, Placebo to match valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years and older
Enrollment
2,572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
32
States / cities
Andalusia, Alabama • Mobile, Alabama • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 27, 2026, 2:13 AM EDT
Withdrawn Phase 2 Interventional

Mechanism(s) Underlying Cardiovascular Effects of ARB/NEP Inhibition - Aim 2

NCT03005184
View directory record Official record
Conditions
Heart Failure NYHA Class I, Heart Failure NYHA Class II, Heart Failure NYHA Class III
Interventions
Valsartan 80 mg bid, Enalapril 10 mg bid, Sacubitril-Valsartan 200 mg bid, Icatibant, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 2 Interventional Results available

LCZ696 Compared to Valsartan in Patients With Chronic Heart Failure and Preserved Left-ventricular Ejection Fraction

NCT00887588
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
LCZ696, Valsartan, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
11
States / cities
Little Rock, Arkansas • Chicago, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

NCT00240448
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
100
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2013 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of Valsartan and Nebivolol/Valsartan in Hypertensive Patients With LVH

NCT03180593
View directory record Official record
Conditions
Hypertension Complicated, Hypertrophy, Left Ventricular, Blood Pressure
Interventions
Valsartan 80 mg
Drug
Lead sponsor
Trinity Hypertension & Metabolic Research Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

SMOOTH - Blood Pressure Control in Diabetic/Obese Patients

NCT00239538
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus, Type 2
Interventions
telmisartan combined with hydrochlorothiazide (80/12.5 mg), valsartan combined with hydrochlorothiazide (160/12.5mg)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 47 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2013 · Synced Sep 27, 2026, 2:13 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 27, 2026, 2:13 AM EDT
Recruiting Phase 3 Interventional

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

NCT02735707
View directory record Official record
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 4 Interventional

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

NCT00168779
View directory record Official record
Conditions
Hypertension
Interventions
telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
1,185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
113
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Sep 27, 2026, 2:13 AM EDT
Withdrawn Phase 4 Interventional

Blood Pressure Lowering in Acute Stroke Trial

NCT01400256
View directory record Official record
Conditions
Stroke, Acute
Interventions
Valsartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 8, 2016 · Synced Sep 27, 2026, 2:13 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2011 · Synced Sep 27, 2026, 2:13 AM EDT